ASCO data bring new markets within reach for two AstraZeneca therapies
The challenge for AZ’s Tagrisso, Enhertu will be persuading doctors to adopt genetic testing
AstraZeneca stole the show at ASCO on Friday with data that should help propel its top-grossing cancer drug and one of its newest market entrants into broadly expanded patient populations, as long as physicians adopt genetic testing in the new indications.
AstraZeneca plc (LSE:AZN; NYSE:AZN) reported at the American Society of Clinical Oncology meeting that Tagrisso osimertinib increased disease-free survival in an adjuvant setting for early-stage, EGFR-mutant non-small cell lung cancer (NSCLC), setting it on a path to become the first targeted therapy in the adjuvant setting for the indication...